Navigation Links
Clinical trial seeks to determine whether platelet-rich plasma can ease the pain of osteoarthritis
Date:3/22/2011

For years, doctors have used platelet-rich plasma, or PRP, to promote healing after surgery. Now, Rush University Medical Center is studying whether PRP can help relieve knee pain in patients with mild to moderate osteoarthritis.

PRP contains growth factors that promote cell proliferation and is prepared from the patient's own blood tissue. It has received popular attention recently because of its use in treating sports injuries in professional athletes, but the jury is still out on whether it is effective.

"There have been few controlled clinical trials, and results are inconsistent, but data so far suggests that it could be a promising treatment for healing in a variety of tissues," said Dr. Brian Cole, orthopedic surgeon and head of the cartilage restoration center at Rush. "The therapy will not be a cure for osteoarthritis, but it could help put off the day when a patient will need to get a knee implant." Cole is professor of orthopedic surgery at Rush University and head team physician for the Chicago Bulls.

At present, the standard of care is either corticosteroid injections, which may provide relief for about three months, or synthetic lubricants containing hyaluronic acid, which can last for up to a year.

In the double-blind, randomized, controlled study, 100 patients will receive either hyaluronic acid or PRP. The PRP is prepared from 10 millimeters of the patient's own blood. The blood is spun in a centrifuge to separate the platelets from the red and white blood cells. The platelets are then injected into the knee joint using ultrasound imaging to guide placement.

Patients will receive three injections over three weeks and will be monitored for two years. In periodic clinical exams, the physician will assess pain and knee function. In addition, a teaspoon-size sample will be taken of the synovial fluid around the knee joint to test for molecular changes that may indicate a shift in the balance of anabolic factors that increase the buildup of tissue and catabolic factors that break it down. An imbalance in these factors has been implicated in the deterioration of cartilage that leads to osteoarthritis.


'/>"/>

Contact: Sharon Butler
Sharon_Butler@rush.edu
312-942-7816
Rush University Medical Center
Source:Eurekalert

Related medicine news :

1. Jefferson clinical trial: Can a cholesterol drug prevent colon cancer?
2. Clinical trial for dry mouth funded by international oral care award
3. Revitalizing Cancer Clinical Trials -- March 21 symposium
4. Novel clinical trial aims to reduce recurrence of aggressive breast cancer
5. Clinical observation leads to lung cancer discovery
6. Study reveals security weaknesses in file-sharing methods used in clinical trials
7. UT Southwestern launches clinical trial for treatment of breast cancer using CyberKnife
8. Elsevier/MEDai enhances real-time clinical surveillance system for hospitals
9. Few physicians refer patients to cancer clinical trials
10. Older adults often excluded from clinical trials
11. New clinical trial to determine ovarian cancer risks in African-American women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... ... February 20, 2017 , ... Silverado today is pleased ... open and operate a state-of-the-art memory care community in Alexandria, Virginia. The new community ... site just outside of Old Town. , The three-story community with underground parking ...
(Date:2/20/2017)... Pittsburgh, PA (PRWEB) , ... February 20, 2017 , ... ... mechanism of thyroid cancer, as well as a marker that may predict response to ... those with many other types of cancer as well. The new findings were published ...
(Date:2/20/2017)... ... February 20, 2017 , ... Today, ... Document Router (BDR), the first IoT device from Biscom designed to deliver confidential ... will debut BDR at HIMSS17 and will be conducting demonstrations at ...
(Date:2/20/2017)... ... 2017 , ... ReportingMD, a Population Health Software Company, is pleased to announce a move to ... location will triple the size of the previous location while bringing life back to a ... , “We are excited to expand our footprint to better serve our growing client ...
(Date:2/20/2017)... , ... February 20, 2017 , ... Chuck E. Cheese’s® ... Sensitive Sundays, a joint event at Chuck E. Cheese’s locations throughout New England, New ... special needs, the opportunity to experience the fun of visiting Chuck E. Cheese’s in ...
Breaking Medicine News(10 mins):
(Date:2/20/2017)... 2017  This Report analyzes the worldwide markets for Pharmaceutical Contract ... Dosage Forms, and Liquid & Semi-solid Dosage Forms. The report provides ... Japan , Europe , ... Read the full report: http://www.reportlinker.com/p04707109-summary/view-report.html ... Annual estimates and forecasts are provided ...
(Date:2/20/2017)... Feb. 20, 2017 Report analyzes the ... the following Product Segments: Ambulatory Infusion Pumps, Enteral ... Pumps, PCA Infusion Pumps, and Syringe Infusion Pumps. ... US, Canada, Japan, Europe, Asia-Pacific, Latin America, and ... report: http://www.reportlinker.com/p04707120-summary/view-report.html Annual estimates and ...
(Date:2/20/2017)... 20, 2017  This report analyzes the worldwide markets for ... The report provides separate comprehensive analytics for the US, ... , Europe , Asia-Pacific ... Rest of World. Read the full ... forecasts are provided for the period 2015 through 2022. ...
Breaking Medicine Technology: